LBT Innovations Ltd is an Australian developer of clinical and diagnostic technology. Based in Adelaide, South Australia, the Company was formed in 2004 and listed on the Australian Securities Exchange in July 2006 (ASX: LBT).

In April 2007, LBT Innovations signed an agreement with world-leading, clinical diagnostic company bioMérieux for the commercialisation of its MicroStreak® technology.The first application of the technology was launched in late 2008 across the global pathology markets and is marketed by bioMerieux as the PREVI Isola.

LBT Innovations plans to progress the development of its MicroStreak® technology into other markets, while leveraging existing relationships to build a new technology pipeline for future growth. The Company’s mission is to become a global leader in innovative automation technologies for medical and scientific laboratories.

LATEST NEWS

17 August 2010

Announcement

Preliminary Final Report 2010 (App 4E)

Appendix 4C June 2010

PREVI™ Isola poster

PREVI™ Isola presentation by John Glasson

Bioshares article on LBT Innovations

First Australian PREVI Isola sale made to Melbourne Pathology

Innovative Medical Products Showcased at MD&M East Ceremony